Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cyclerion Therapeutics, Inc.    CYCN

CYCLERION THERAPEUTICS, INC.

(CYCN)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/22/2020 05/26/2020 05/27/2020 05/28/2020 05/29/2020 Date
4.29(c) 4.29(c) 4.37(c) 4.04(c) 3.98(c) Last
115 740 203 876 134 296 100 103 342 486 Volume
+6.98% 0.00% +1.86% -7.55% -1.49% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -96,0 M - -
Net cash position 2020 222 M - -
P/E ratio 2020 -1,98x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -113 M - -
Net cash position 2021 133 M - -
P/E ratio 2021 -3,83x
Yield 2021 -
Capitalization 110 M 110 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 94
Free-Float 87,4%
More Financials
Company
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for serious and orphan diseases. The Company develops guanylate cyclase (sGC) stimulators. The Company’s portfolio includes five sGC stimulator programs: olinciguat, praliciguat, IW-6463 and two organ-targeted programs. Olinciguat is an oral, once-daily... 
More about the company
Latest news on CYCLERION THERAPEUTICS, IN
05/04CYCLERION THERAPEUTICS : Management's Discussion and Analysis of Financial Condi..
AQ
04/14CYCLERION THERAPEUTICS, INC. : Results of Operations and Financial Condition, Re..
AQ
04/13CYCLERION THERAPEUTICS : Updates Corporate Progress
AQ
04/10Cyclerion Updates Corporate Progress
GL
03/12CYCLERION THERAPEUTICS : Management's Discussion and Analysis of Financial Condi..
AQ
03/05CYCLERION THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Finan..
AQ
01/13Cyclerion announces IW-6463 phase 1 healthy volunteer study results that supp..
GL
01/13CYCLERION THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements an..
AQ
2019Cyclerion to Present at the J.P. Morgan Healthcare Conference
GL
2019Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference
GL
2019CYCLERION THERAPEUTICS : Management's Discussion and Analysis of Financial Condi..
AQ
2019CYCLERION THERAPEUTICS : Announces Topline Phase 2 Results for sGC Stimulator Pr..
AQ
2019CYCLERION THERAPEUTICS, INC. : Results of Operations and Financial Condition, Co..
AQ
2019Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabe..
GL
2019Cyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator P..
GL
More news
News in other languages on CYCLERION THERAPEUTICS, IN
05/04CYCLERION THERAPEUTICS : Management's Discussion and Analysis of Financial Condi..
04/14CYCLERION THERAPEUTICS, INC. : Results of Operations and Financial Condition, Re..
04/13CYCLERION THERAPEUTICS : Updates Corporate Progress
04/10Cyclerion Updates Corporate Progress
03/12CYCLERION THERAPEUTICS : Management's Discussion and Analysis of Financial Condi..
More news
Chart CYCLERION THERAPEUTICS, INC.
Duration : Period :
Cyclerion Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CYCLERION THERAPEUTICS, IN
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 5,00 $
Last Close Price 3,98 $
Spread / Highest target 25,6%
Spread / Average Target 25,6%
Spread / Lowest Target 25,6%
EPS Revisions
Managers
NameTitle
Peter M. Hecht Chief Executive Officer & Director
Mark G. Currie President & Chief Scientific Officer
Marsha H. Fanucci Chairman
William I. Huyett Chief Financial Officer
Christopher I. Wright Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
CYCLERION THERAPEUTICS, INC.46.32%110
LONZA GROUP33.49%36 433
IQVIA HOLDINGS INC.-3.23%28 553
SEATTLE GENETICS, INC.37.59%27 213
MODERNA, INC.214.42%23 913
CELLTRION, INC.17.96%23 085